Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1840
Peer-review started: May 30, 2022
First decision: July 6, 2022
Revised: July 7, 2022
Accepted: August 30, 2022
Article in press: August 30, 2022
Published online: September 27, 2022
Processing time: 115 Days and 13.3 Hours
Core Tip: The scarcity of viable organs, which is quite limited, the waiting lists that reflect chronicity and the increase in time to transplantation, and the rate of physical deterioration resulting in death while waiting for a helpful organ for transplantation, promote the search for new ways, strategies, and protocols to increase the group of donors acceptable for transplantation, such as donors in asystole, donors with tumor processes, or donors with previous infection. The application of antivirals against the hepatitis C virus (HCV), with unprecedented success in the elimination of the pathogen, has led to the use of HCV-positive donors as optimal donors for HCV-negative recipients, with survival similar to that of both HCV-negative donors and recipients, which supports the use of these HCV-positive donors without restrictions.
